Guggenheim Capital LLC Aveo Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

  • $12 Billion
  • Q4 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$8.48 - $14.97 $117,439 - $207,319
13,849 New
13,849 $207,000

Others Institutions Holding AVEO

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About AVEO PHARMACEUTICALS, INC.

AVEO Quotes by TradingView
  • Ticker AVEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,676,000
  • Description
  • AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...
More about AVEO
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email